Clinical trials for Systemic lupus erythematosus
100 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGEarly Phase 1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGN/ANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI) · PI: Cristina M Lanata, M.D.
- RECRUITINGPhase 2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPhase 3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc. · PI: Medical Responsible
- RECRUITINGEarly Phase 1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEarly Phase 1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine · PI: Meiping Lu
- RECRUITINGN/ANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · PI: Qiubai Li, Professor
- RECRUITINGPhase 4NCT07087912Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic DiseasesUniversity of Sao Paulo General Hospital
- RECRUITINGPHASE1, PHASE2NCT07523542SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory LupusBeijing Biotech
- RECRUITINGPhase 1NCT07219563Alnuctamab for Refractory SLE (LATTE Study)Icahn School of Medicine at Mount Sinai · PI: Chrisanna Dobrowolski, MD
- RECRUITINGPhase 4NCT06875960A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132Bristol-Myers Squibb · PI: Bristol-Myers Squibb
- RECRUITINGEarly Phase 1NCT07246096Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune DiseasesChanghai Hospital
- RECRUITINGPhase 1NCT07371468A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)GlaxoSmithKline · PI: GSK Clinical Trials
- RECRUITINGPhase 1NCT07403097Study of CD19 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGPhase 1NCT07331272A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)Nanjing Legend Biotech Co.
- RECRUITINGPhase 1NCT07413341A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune DiseasesTherorna · PI: Hu ji Xu
- RECRUITINGPhase 4NCT06594068Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersAstraZeneca · PI: Darin Brimhall, MD
- RECRUITINGPhase 2NCT07311200A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)InventisBio Co., Ltd · PI: Xiaofeng
- ENROLLING BY INVITATIONPhase 2NCT07266090A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)Viatris Pharmaceuticals Co., Ltd.
- RECRUITINGNCT07330245Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.AstraZeneca
- RECRUITINGPhase 1NCT07323173A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus ErythematosusNanjing Leads Biolabs Co.,Ltd · PI: xianmin meng
- RECRUITINGPhase 1NCT07444307A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus ErythematosusHangzhou Qihan Biotech Co., Ltd. · PI: Mengtao Li, PhD
- RECRUITINGPhase 2NCT07340463The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil TreatmentNanjing University School of Medicine
- RECRUITINGPhase 2NCT07260877A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus ErythematosusVentus Therapeutics U.S., Inc.
- RECRUITINGPhase 1NCT07201558Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsAstraZeneca
- RECRUITINGN/ANCT07180537Creating Health Course Study for People With Rheumatological ConditionsTerry L. Wahls · PI: Terry L Wahls, MD, Other
- RECRUITINGPhase 1NCT05018858Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for LupusThe Foundation for Orthopaedics and Regenerative Medicine · PI: Chadwick Prodromos, MD
- RECRUITINGN/ANCT07282392Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)University of Utah · PI: Dan Kaufmann, PhD
- RECRUITINGPhase 1NCT07305116CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- ACTIVE NOT RECRUITINGNCT07053137A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.Yipeng Liu
- RECRUITINGPhase 1NCT07236762An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesChina Immunotech (Beijing) Biotechnology Co., Ltd.
- RECRUITINGPhase 2NCT07363460Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNHaisco Pharmaceutical Group Co., Ltd. · PI: bicheng Liu
- RECRUITINGPhase 1NCT07236801Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune DiseasesChina Immunotech (Beijing) Biotechnology Co., Ltd.
- RECRUITINGNCT06795893The Anifrolumab PRIM ProgramAstraZeneca · PI: Syd Philips
- RECRUITINGPhase 1NCT07361094Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune DiseasesBeijing Boren Hospital
- RECRUITINGEarly Phase 1NCT07339540the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune DiseasesTongji Hospital
- RECRUITINGPhase 1NCT07233642Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLEThe Children's Hospital of Zhejiang University School of Medicine · PI: Jianhua Mao, MD
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07221565Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine ForecastingTruway Health, Inc. · PI: Gavin Solomon, President & CEO
- RECRUITINGNCT07352332Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTEThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGEarly Phase 1NCT07193810A Study of CC312 for Relapsed/Refractory Autoimmune DiseasesCytoCares Inc
- RECRUITINGPHASE1, PHASE2NCT07185269The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLESunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- RECRUITINGNCT07053891LUPKYNIS Drug-use Results SurveyOtsuka Pharmaceutical Co., Ltd.
- RECRUITINGPhase 1NCT07177911Safety and Efficacy Study of CC312 for Moderate to Severe SLECytoCares Inc
- RECRUITINGEarly Phase 1NCT07174843An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune DiseasesShanghai Cell Therapy Group Co.,Ltd
- RECRUITINGPHASE1, PHASE2NCT07010835Study of YK012 in Moderate to Severe Systemic Lupus ErythematosusExcyte Biopharma Ltd
- RECRUITINGPhase 4NCT07077486Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung DiseaseTongji Hospital
- RECRUITINGPhase 1NCT07123519A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune DiseasesChina Immunotech (Beijing) Biotechnology Co., Ltd.
- RECRUITINGPhase 1NCT07104721A Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesChina Immunotech (Beijing) Biotechnology Co., Ltd.
- RECRUITINGPhase 2NCT06570798A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesAmgen · PI: MD
- RECRUITINGEarly Phase 1NCT07072611Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy ParticipantsNoxopharm Limited
- RECRUITINGPhase 1NCT07031713Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLEUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ACTIVE NOT RECRUITINGN/ANCT07102238Lupus Arthritis: Muscoloskeletal Ultrasound as Clinical Outcome of Peripheral Blood and Synovial Deep PhenotypingFondazione Policlinico Universitario Agostino Gemelli IRCCS · PI: Maria Antonietta D'Agostino
- ENROLLING BY INVITATIONPhase 1NCT07038447A Study of KITE-363 in Participants With Refractory Autoimmune DiseasesKite, A Gilead Company · PI: Kite Study Director
- RECRUITINGPhase 1NCT06892145Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGNCT07397728" TREX1 Gene Mutations and Their Role in Systemic Lupus ErythematosusSouth Valley University · PI: Eisa Mohammed Hegazy, Professor
- RECRUITINGN/ANCT06426316The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.University Hospital, Clermont-Ferrand · PI: Xavier MOISSET
- RECRUITINGPhase 1NCT06980597A Study of OL-108 in Relapsed/Refractory Autoimmune DiseasesBeijing GoBroad Hospital
- RECRUITINGPhase 3NCT06711887Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)Novartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGPhase 1NCT06881290Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus ErythematosusChinese SLE Treatment And Research Group
- RECRUITINGPHASE1, PHASE2NCT06839976CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for LupusChildren's Hospital of Philadelphia · PI: Caitlin Elgarten, MD
- RECRUITINGPhase 1NCT06916806A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.AstraZeneca
- RECRUITINGPhase 3NCT06904729Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in ChildrenGuangzhou Women and Children's Medical Center
- ACTIVE NOT RECRUITINGPhase 1NCT06544330A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic DiseaseSynthekine
- RECRUITINGPHASE1, PHASE2NCT06947460CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAHBeijing GoBroad Hospital
- RECRUITINGN/ANCT06902844Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)Tongji Hospital
- ENROLLING BY INVITATIONEarly Phase 1NCT06661213Tapinarof for Cutaneous Lupus ErythematosusNorthwestern University · PI: Paras Vakharia
- RECRUITINGEarly Phase 1NCT06946485Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus ErythematosusThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · PI: Lingyun Sun
- RECRUITINGNCT07150000Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and EfficacyUniversity of Bonn
- RECRUITINGPhase 1NCT07136389Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus ErythematosusBiocad · PI: Arina V Zinkina-Orikhan, PhD
- ACTIVE NOT RECRUITINGN/ANCT07155369UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune DiseasesThe Affiliated Hospital of Xuzhou Medical University
- ENROLLING BY INVITATIONN/ANCT07394361The Effect of Clinical Pilates Training on Fatigue, Emotional State, Functional Capacity, Sleep and Quality of Life in Women With Systemic Lupus ErythematosusEmir İbrahim IŞIK
- ACTIVE NOT RECRUITINGNCT06898489Adjunctive Yu-Tone Music Therapy for Systemic Lupus Erythematosus: a Prospective Cohort StudyYijun Luo
- RECRUITINGN/ANCT06435468Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory DiseasesHospices Civils de Lyon
- RECRUITINGPhase 1NCT06676631NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus NephritisGuangdong Provincial People's Hospital · PI: Xueqing Yu
- RECRUITINGPhase 1NCT06349343CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus ErythematosusUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · PI: Qiubai Li, Professor
- RECRUITINGNCT06887517Chinese Rheumatism Biobank(CRB)Chinese SLE Treatment And Research Group
- ACTIVE NOT RECRUITINGPhase 1NCT06255028A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune DiseasesCentury Therapeutics, Inc.
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT06888973Mesenchymal Stem Cells Infusion in Patients With Autoimmune DiseasesNational Institute of Blood and Marrow Transplant (NIBMT), Pakistan · PI: Memoona Haider, MBBS, FCPS
- RECRUITINGEarly Phase 1NCT06792799Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGEarly Phase 1NCT06653556A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus ErythematosusUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPhase 1NCT06737380UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) PatientsLiveKidney.Bio
- RECRUITINGPhase 1NCT06710717Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)National University of Malaysia
- RECRUITINGNCT06365359Systemic Lupus Erythematosus and Chlordecone Impregnation in MartiniqueUniversity Hospital Center of Martinique · PI: Benoît SUZON, PhD
- RECRUITINGNCT07148115Pregnancies Before the Diagnosis of Systemic Lupus ErythematosusUniversity of Algiers · PI: Wafia-Nadia Nibouche-Hattab, Professor of medicine
- RECRUITINGPhase 2NCT06794008BCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesPeking University People's Hospital · PI: Zhanguo Li
- RECRUITINGPhase 1NCT06465147REACT-01: Reversing Autoimmunity Through Cell TherapySeattle Children's Hospital · PI: Shaun Jackson, MD
- RECRUITINGPhase 1NCT06789107Blinatumomab in Refractory Active Childhood Systemic Lupus ErythematosusMao Jianhua · PI: Jianhua Mao, PhD, MD
- ENROLLING BY INVITATIONN/ANCT05693571Engagement in CHildhood-Onset Systemic LupusMontefiore Medical Center · PI: Tamar Rubinstein, MD, MS
- RECRUITINGNCT07313475Evaluation of the Cryocheck HexLA Integrated TCA for the Detection of Lupus AnticoagulantUniversity Hospital, Strasbourg, France
- RECRUITINGNCT06796569Systemic Immune Inflammatory Index in Systemic Lupus ErythematosusSohag University
- RECRUITINGPhase 1NCT06657703Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.HC Biopharma Inc.
- RECRUITINGNCT06642402Monitoring Lupus Nephritis Through Urinary Extracellular VesiclesKolding Sygehus · PI: Anne F Christensen, Chief of Medicine, MD, phd
- ENROLLING BY INVITATIONPhase 1NCT06375993A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune DiseaseAdicet Therapeutics
- RECRUITINGPhase 1NCT06691152Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus ErythematosusThe Children's Hospital of Zhejiang University School of Medicine · PI: Jianhua Mao
- RECRUITINGPHASE1, PHASE2NCT06585514Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus ErythematosusBeijing GoBroad Hospital
- ACTIVE NOT RECRUITINGPhase 4NCT06677801Immune Cell Subsets in SLE Patients Treated with TelitaciceptSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE1, PHASE2NCT06675422JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · PI: Sanbin Wang, Doctor
- RECRUITINGPhase 1NCT06335979An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).Novartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- ACTIVE NOT RECRUITINGN/ANCT05818254The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRBDuke University · PI: Megan E Clowse, MD